Where Tech Meets Bio

Where Tech Meets Bio

Home
Weekly Highlights
Deep Dives
Features
About
From Biohacking to Healthcare: The Growing Pains of the Longevity Industry
Part I: A tour of the therapeutic strategies targeting the hallmarks of aging—from cellular reprogramming to senolytics, mTOR inhibitors, and immune…
 • Louise von Stechow and BiopharmaTrend
Weekly Tech+Bio #81: AI Agents at the Cancer Conference
AI-pharma deals track toward a 12x increase in five years, Life Biosciences takes cell reprogramming to Phase 1, and Jeito closes Europe's largest…
 • Roman Kasianov, Andrii Buvailo, PhD, and BiopharmaTrend
Weekly Tech+Bio #80: Organoids on Artemis II
Anthropic's $400M AI biotech acqui-hire, CRO stocks reprice, new EMA draft, and pharma's spring acquisition spree
 • Roman Kasianov, Andrii Buvailo, PhD, and BiopharmaTrend
Everyone is Launching AI Agents. What's Being Deployed?
A check-in on biopharma's agentic AI buildout
 • Roman Kasianov and Andrii Buvailo, PhD

March 2026

Weekly Tech+Bio Highlights #79: A Pharma Factory in an Egg
Lilly's $2.75B generative chemistry deal and why AI research might be locked into 'hypernormal' science
 • Roman Kasianov and Andrii Buvailo, PhD
Weekly Tech+Bio Highlights #78: AI Agents Rush In
Roche and Lilly scale up pharma's biggest AI supercomputers, a billion-dollar startup unveils its virtual cell, and agents are everywhere
 • Roman Kasianov, Andrii Buvailo, PhD, and BiopharmaTrend
Weekly Tech+Bio Highlights #77: AI-Guided mRNA Vaccine Shrinks Dog's Cancer
Google's AI doctor passes its first clinic test, China's first take-home BCI, OpenFold3 goes fully open, and arXiv is going independent
 • BiopharmaTrend, Roman Kasianov, and Andrii Buvailo, PhD
Simulating the Control Arm: Virtual Patients at the Trial Bottleneck
Digital twins promise smaller, faster trials, and the regulatory scaffolding is forming. But there’s still a validation gap.
 • BiopharmaTrend
Weekly Tech+Bio Highlights #76: Neurons, Genomes, and Self-Driving Labs
Living neurons play DOOM, Lilly uses digital twins to scale GLP-1 production, generative genomics are now in Nature, and a rice-grain-sized retinal…
 • BiopharmaTrend, Roman Kasianov, and Andrii Buvailo, PhD
The €25B vs €219B Problem: Europe's Plan to Fix Biotech
Brussels is counting on new laws, sovereign AI, and billions in fresh capital to close the gap. The clock is ticking.
 • BiopharmaTrend
Weekly Tech+Bio Highlights #75: Lilly's Supercomputer, FDA's One-Trial Shift, and China Deals Get Pricey
Generate:Bio's $400M IPO, federated ADMET modeling across five pharma companies, Gilead's $7.8B CAR-T buyout, and an $80M AI-enabled brain health clinic…
 • BiopharmaTrend and Roman Kasianov

February 2026

© 2026 BiopharmaTrend (BPT Analytics Ltd) · Privacy ∙ Terms ∙ Collection notice
Start your SubstackGet the app
Substack is the home for great culture